Stem Cell Therapy + Exosome Therapy
Documented synergy between Stem Cell Therapy and Exosome Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Cutting-edge regenerative medicine to rejuvenate from within
Definition and how it works: Stem cell therapy uses undifferentiated cells with the capacity for self-renewal and differentiation into multiple cell types. The most common sources in longevity clinics are mesenchymal stem cells (MSCs) derived from adipose tissue, bone marrow or umbilical cord. These cells are administered intravenously or intra-articularly and act through paracrine effects: they secrete factors that modulate inflammation, stimulate regeneration and rejuvenate the tissue microenvironment.
Stem cell therapy uses undifferentiated cells with the capacity for self-renewal and differentiation into multiple cell types. The most common sources in longevity clinics are mesenchymal stem cells (MSCs) derived from adipose tissue, bone marrow or umbilical cord. These cells are administered intravenously or intra-articularly and act through paracrine effects: they secrete factors that modulate inflammation, stimulate regeneration and rejuvenate the tissue microenvironment.
Origin and history
Stem cells were first described by McCulloch and Till in 1961 in mice. The first successful bone marrow transplant was performed in 1968. The use of MSCs in longevity and rejuvenation gained clinical traction from 2015 onwards.
1. Assessment and blood work Full biomarker panel, medical history and indication definition.
2. Cell harvesting Adipose tissue extraction (mini-lipoaspiration) or use of GMP allogeneic donor MSCs.
3. Processing Isolation and expansion in a GMP-certified laboratory. Quality control and microbiological safety testing.
4. IV or local administration Slow IV infusion (60–90 min) or intra-articular injection under ultrasound guidance.
5. Follow-up Review at 1 month, 3 months and 6 months with biomarkers and clinical evaluation.
| Equipment | Brand / Model | Technical detail |
|---|---|---|
| GMP laminar flow cabinet | Esco / Thermo Scientific | Class A sterile cell processing. European certification. |
| Cell cryopreservation | Chart Biomedical / Taylor-Wharton | Liquid nitrogen storage at -196 °C for viability preservation. |
Clinics on LongevityMap declare their exact equipment for objective scoring.
Cutting-edge regenerative medicine to rejuvenate from within
€2,000–15,000 per protocol
1–3 sessions annually (protocol varies by indication)
Prices vary by clinic, equipment and practitioner experience. LongevityMap compares price and quality so you always make the best decision.
Documented synergy between Stem Cell Therapy and Exosome Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Stem Cell Therapy and PRP (Platelet-Rich Plasma). Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Stem Cell Therapy and Hyperbaric Chamber. Canonical combination in literature · see protocol and evidence.
View comparison →We are collecting signed consents under GDPR Art. 9.2.a. First verified testimonials will appear once the first real clinics are onboarded (Q4 2026).
Hundreds of clinical trials registered on ClinicalTrials.gov explore MSCs in over 80 diseases. Mechanisms of action include exosome secretion, anti-inflammatory interleukins (IL-10, TGF-β) and growth factors. Studies from Stanford's Institute for Stem Cell Biology show a 70% reduction in systemic inflammatory markers following IV MSC infusion.
SR/MA 28 RCTs (knee OA): intra-articular MSC significantly improved pain (VAS, KOOS) and function (KOOS ADL/sports/symptoms) vs control. No structural changes on MRI (WORMS); effect is primarily symptomatic.
SR/MA 15 RCTs: MSC reduce acute (OR 0.47) and chronic (OR 0.50) graft-versus-host disease incidence after hematopoietic stem cell transplantation and improve response in steroid-refractory acute GVHD (OR 1.50).
SR + Network MA 16 RCTs (n=622 knee OA): repeated MSC injections provide greater pain and function improvement at 6-12 months than single dose, but with higher adverse event incidence. Risk/benefit must be weighed.
2025 translational study: umbilical cord MSC exosomes (hUC-MSC-Exos) reduced joint inflammation and promoted cartilage regeneration in preclinical models. Randomised dose-ascending clinical trial confirmed safety and preliminary efficacy in OA patients.
Last bibliographic review: 2026-03-28.
Allogeneic MSCs from certified donors have a well-documented safety profile. The risk of immune reaction is low because MSCs possess immunomodulatory properties. However, only GMP-certified sources with full traceability should be used.
Reported effects last between 12 and 24 months depending on the indication. For general longevity, many patients undergo an annual maintenance session.
Yes. The AEMPS (Spanish Medicines Agency) strictly regulates the production and application of stem cell therapies. Clinics operating legally in Spain must hold specific authorisation and use registered products.
Tell us your goal and budget. We cross-reference 500+ clinical parameters and generate 3 personalised plans with Stem Cell Therapy.
Generate My Protocol for freeLongevityMap content is for informational and educational purposes only. It does not constitute personalised medical advice. Always consult a healthcare professional before starting any treatment. Our team · Methodology